Valuation
- Market cap
- 396,732,000
- Revenue TTM
- $0
- Net income TTM
- $-99,350,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 2,954,700
- Avg volume
- 1,506,444
- Day's range
- $4.07 – $4.36
- Shares out
- 95,829,000
- Stochastic %K
- 35%
- Beta
- 0.01
- Analysts
- Strong Sell
- Price target
- $18.83
Company profile
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880...
Show more
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 702 825 9872
- Website
- https://zurabio.com
- Address
- 1489 W. Warm Springs Road, Suite 110, Henderson, United States
Latest news
No headlines yet.
